Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

First- and Second-Generation Antipsychotics for Children and Young Adults

Slide: 27 of 43

Results of Comparative Effectives Studies: SGAs Versus SGAs

For pediatric use, second-generation antipsychotics (SGAs) have been compared directly to other SGAs for treatment effects on schizophrenia.

Olanzapine was compared with risperidone. In a meta-analysis of 3 studies of 136 participants, no statistically significant difference in the Brief Psychiatric Rating Scale (BPRS) score was found in 3 studies of 136 participants. An analysis of 2 studies of 111 participants demonstrated no statistically significant difference in Clinical Global Impressions Scale (CGI-S) score. A meta-analysis of 3 studies of 143 participants demonstrated no statistically significant difference in Positive and Negative Syndrome Scale (PANSS) scores.

Olanzapine was compared with clozapine. In a meta-analysis of 2 studies of 27 participants, no statistically significant difference in BPRS score was found; the statistically valid range for the effect size is from 10.82 points less to 0.64 points more. In a meta-analysis of 2 studies of 64 participants, no statistically significant difference in CGI-S score was found; the statistically valid range for the effect size is from 1.01 points less to 0.08 points more. In a meta-analysis of 2 studies of 64 participants, no statistically significant difference in CGI-S score was found; the statistically valid range for the effect size is from 15.45 points less to 5.36 points more.

For all comparisons, the strength of evidence is low.

Statistical Abbreviations: 95% CI = 95-percent confidence interval; NSD = no statistically significant difference